Pages that link to "Q37661688"
Jump to navigation
Jump to search
The following pages link to The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation (Q37661688):
Displaying 28 items.
- Economic evaluations of personalized medicine: existing challenges and current developments (Q26797183) (← links)
- Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature (Q28073025) (← links)
- Evidence synthesis to inform model-based cost-effectiveness evaluations of diagnostic tests: a methodological review of health technology assessments (Q30358653) (← links)
- Pharmacogenetics of antipsychotics (Q33836837) (← links)
- A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer (Q33911180) (← links)
- Personalized medicine in psychiatry: problems and promises (Q34726454) (← links)
- Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer (Q35109837) (← links)
- Genomics and pharmacogenomics of schizophrenia (Q37780792) (← links)
- Acceptance of biomarker-based tests for application in clinical practice: criteria and obstacles (Q37803527) (← links)
- Pharmacogenomics of antipsychotics efficacy for schizophrenia (Q37832287) (← links)
- Pharmacogenetics of response to antipsychotics in patients with schizophrenia (Q37952823) (← links)
- Utility and adoption of CYP2D6 and CYP2C19 genotyping and its translation into psychiatric clinical practice (Q37962959) (← links)
- The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review (Q38167693) (← links)
- Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes (Q38426328) (← links)
- New drug developments in psychosis: Challenges, opportunities and strategies (Q38926246) (← links)
- Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come? (Q38975693) (← links)
- Through a glass darkly: economics and personalised medicine (Q39145520) (← links)
- Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. (Q42788951) (← links)
- Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population (Q43479196) (← links)
- CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles (Q46828988) (← links)
- The effect of CYP1A2 gene polymorphism on the metabolism of theophylline (Q49637368) (← links)
- A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events (Q50432917) (← links)
- Future Trends in the Pharmacogenomics of Brain Disorders and Dementia: Influence of APOE and CYP2D6 Variants. (Q55266735) (← links)
- Informing resource allocation decision making: economic evaluations of pharmacogenetic tests (Q57697486) (← links)
- CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia (Q57820328) (← links)
- No Effect of Dose Adjustment to the Genotype in Patients With Severe Mental Illness (Q58797266) (← links)
- The effect of CYP2D6 variation on antipsychotic-induced hyperprolactinaemia: a systematic review and meta-analysis (Q89518813) (← links)
- A pharmacogenetic intervention for the improvement of the safety profile of antipsychotic treatments (Q92185882) (← links)